Amenamevir

Drug Profile

Amenamevir

Alternative Names: Amenalief; ASP-2151; M5220

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Maruho
  • Class Amides; Antivirals; Oxadiazoles; Small molecules
  • Mechanism of Action DNA helicase-primase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Herpes zoster
  • Phase III Herpes simplex virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections(In volunteers) in United Kingdom (PO, Tablet)
  • 07 Sep 2017 Launched for Herpes zoster in Japan (PO)
  • 03 Jul 2017 Registered for Herpes zoster in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top